Circulation:识别糖代谢异常人群中心血管事件或死亡的新型标志物

2015-11-01 phylis 译 MedSci原创

背景:血清生物标记物可识别心血管(CV)高危人群的预后。在ORIGIN试验中8494名血糖异常受试者的生物信息库血清样本,检测284个生物标记物识别那些心血管高危人群的预后或死亡。方法:多重分析检测每个受试者提供的1毫升血清样本中心脏代谢的生物标志物。除去无法检测及分析的生物标志物后,分析8401受试者的237的生物标志物。应用Cox回归模型识别生物标志物,这种标志物可独立影响是3种不同的预后:心

背景:血清生物标记物可识别心血管(CV)高危人群的预后。在ORIGIN试验中8494名血糖异常受试者的生物信息库血清样本,检测284个生物标记物识别那些心血管高危人群的预后或死亡。

方法:多重分析检测每个受试者提供的1ml血清样本中的心脏代谢的生物标志物。除去无法检测及分析的生物标志物后,分析8401受试者的一组237个生物标志物。应用Cox回归模型识别生物标志物,这种标志物可独立影响是3种不同的预后:心肌梗死、中风或心血管死亡;因心衰住院增加或血管重建;各种原因引起的死亡。

结果:当增加临床变量时,在随访期间,10个生物标志物是1405名发生心血管预后的独立决定因素,9个生物标志物(那10个中包括8个)是2435名延伸预后的决定因素,15(包括10个心血管的生物标志物)是1340人死亡的独立决定因素。校正临床变量,2个CV预后及死亡,C统计量分别从0.64增加到0.71,0.68和0.75。

结论:这个实验识别了15种心脏代谢的生物标志物作为糖代谢异常的人们CV预后或死亡的独立危险因素。

原文出处:

Gerstein HC, Paré G, McQueen MJ,et al. Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia.Circulation.2015,Oct 30.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840857, encodeId=5e9c184085e96, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 10 20:37:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643385, encodeId=191b164338534, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 16 03:37:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993508, encodeId=97801993508e3, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Dec 15 08:37:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360579, encodeId=0bf213605e9ab, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631776, encodeId=98bb1631e76f7, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840857, encodeId=5e9c184085e96, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 10 20:37:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643385, encodeId=191b164338534, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 16 03:37:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993508, encodeId=97801993508e3, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Dec 15 08:37:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360579, encodeId=0bf213605e9ab, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631776, encodeId=98bb1631e76f7, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840857, encodeId=5e9c184085e96, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 10 20:37:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643385, encodeId=191b164338534, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 16 03:37:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993508, encodeId=97801993508e3, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Dec 15 08:37:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360579, encodeId=0bf213605e9ab, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631776, encodeId=98bb1631e76f7, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840857, encodeId=5e9c184085e96, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 10 20:37:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643385, encodeId=191b164338534, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 16 03:37:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993508, encodeId=97801993508e3, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Dec 15 08:37:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360579, encodeId=0bf213605e9ab, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631776, encodeId=98bb1631e76f7, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
    2015-11-03 zz70
  5. [GetPortalCommentsPageByObjectIdResponse(id=1840857, encodeId=5e9c184085e96, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 10 20:37:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643385, encodeId=191b164338534, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Mon Nov 16 03:37:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993508, encodeId=97801993508e3, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Dec 15 08:37:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360579, encodeId=0bf213605e9ab, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631776, encodeId=98bb1631e76f7, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Tue Nov 03 13:37:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]

相关资讯

胡大一:关爱糖尿病患者——从“心”开始

糖尿病与心血管疾病(CVD)关系密切,充分认识糖代谢异常与心血管病之间的密切关系,对于心血管疾病多重危险因素的综合防治具有重要意义。Framingham研究30余年随访结果证实,与非糖尿病者相比,糖尿病患者的冠心病、卒中、心力衰竭危险增加2~10倍。中美队列随访至1997年的分析结果显示,糖尿病是中国中年人群冠心病和卒中的独立危险因素,仅次于高血压。中国心血管报告2007提示,中国糖尿病患者缺血性

冠心病及其高危患者的血糖筛查和管理

       大量流行病学与临床研究显示,已进展或未进展至冠心病的心血管疾病患者中,糖代谢异常的流行趋势显著,早期进行糖代谢异常筛查并给予合理的干预可能有助于改善患者心血管预后。然而,基于单纯空腹血糖(FPG)检测易造成较高的漏诊率的缺点,如何有效提高冠心病及其高危患者如高血压、高血脂患者的高血糖检出率是目前广大心血管医生面临的首要问题。   &